Table 1.
ACPA fine-specificities in anti-CCP2+ and anti-CCP- RA and controls
| ACPA fine-specificities | Antibody frequencies (%) | Antibody levels (median)a | |||||
|---|---|---|---|---|---|---|---|
| CCP2+ | CCP2− | Controls | p valueb | CCP2+ | CCP2− | p valuec | |
| Cit-Fibß60–74 | 80.6 | 9.5 | 0.8 | < 0.0001 | 195.3 | 27.1 | < 0.0001 |
| Cit-peptide-5 | 75.4 | 8.6 | 1.1 | < 0.0001 | 81.4 | 27.2 | < 0.0001 |
| Cit-peptide-Z1 | 69.3 | 5.1 | 0.5 | 0.0001 | 167.4 | 38.6 | < 0.0001 |
| Cit-Fibß36–52 | 65.6 | 5.0 | 1.4 | 0.003 | 605.0 | 186.4 | < 0.0001 |
| Cit-Vim60–75 | 63.5 | 2.9 | 1.1 | 0.049 | 641.6 | 321.9 | 0.009 |
| CEP-1 | 60.9 | 4.4 | 1.1 | 0.003 | 678.2 | 316.1 | < 0.0001 |
| cfc1-cyc (CCP1) | 59.9 | 3.8 | 1.1 | 0.009 | 514.7 | 166.0 | < 0.0001 |
| Cit-Fibα563–583 | 57.6 | 2.5 | 1.1 | 0.10 | 444.8 | 144.0 | 0.002 |
| Cit-peptide-Z2 | 49.5 | 2.9 | 0.3 | 0.003 | 150.9 | 58.6 | 0.002 |
| Cit-peptide-1 | 45.0 | 4.7 | 1.9 | 0.02 | 72.7 | 29.2 | < 0.0001 |
| Cit-Fibα621–635 | 42.9 | 4.6 | 1.4 | 0.005 | 384.0 | 123.0 | < 0.0001 |
| Cit-peptide-Bla26 | 39.9 | 4.4 | 1.4 | 0.006 | 80.3 | 48.7 | 0.003 |
| Cit-Vim2–17 | 40.3 | 2.6 | 1.4 | 0.16 | 75.9 | 72.8 | 0.712 |
| Cit-F4(Cit-Cit) | 36.1 | 3.4 | 1.6 | 0.08 | 84.9 | 60.6 | 0.032 |
| Cit-F4(R-Cit) | 29.9 | 2.1 | 1.4 | 0.36 | 86.4 | 80.6 | 0.366 |
| Cit-Fibα580–600 | 24.2 | 2.8 | 1.4 | 0.11 | 264.2 | 197.2 | 0.024 |
| Cit-Fibα36–50 | 17.6 | 4.0 | 1.9 | 0.053 | 422.9 | 265.5 | < 0.0001 |
| Cit-C1 | 10.8 | 1.9 | 1.4 | 0.48 | 69.3 | 87.9 | 0.383 |
| Cit-F4(Cit-R) | 6.2 | 1.8 | 1.1 | 0.34 | 403.0 | 306.5 | 0.382 |
aMedian antibody levels are shown for ACPA+ patients only. P values indicate differences between banti-CCP2− RA and controls or between canti-CCP2+ and anti-CCP2− RA